Immutep (ASX:IMM) clinical trial update and partnerships

0
59



Immutep Limited (ASX:IMM) Executive Director and CEO, Marc Voigt provides an update on the company’s clinical trials, collaboration with large pharma and key milestones.

LEAVE A REPLY

Please enter your comment!
Please enter your name here